Skip to main content

Table 2 Univariate analysis of prognostic factors for progression-free survival

From: Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma

Variables HR (95% CI) P value
Gender
 Male Reference  
 Female 1.634(0.793,3.368) 0.183
ECOG performance
 1 Reference  
 0 0.846(0.485,1.474) 0.555
Hepatitis
 Hepatitis B Reference  
 Other 0.845(0.431,1.656) 0.624
Child–Pugh score
 B Reference  
 A 1.715(0.415,7.088) 0.456
Age (years) 0.987(0.961,1.015) 0.358
AST (µmol/L) 1.004 (0.997,1.010) 0.262
ALT (µmol/L) 1.006 (0.992, 1.020) 0.414
PLR 1.002(0.999, 1.006) 0.244
NLR 0.795(0.653, 0.969) 0.023
Albumin (g/L) 1.004 (0.913, 1.104) 0.934
TB (µmol/L) 0.973(0.933,1.015) 0.200
PT (s) 1.001(0.807,1.241) 0.991
Tumor size 0.979 (0.862, 1.112) 0.744
BCLC stage
 C Reference  
 B 0.557(0.299, 1.037) 0.065
Tumor number
  = 1 Reference  
  ≥ 2 0.551 (0.299, 1.017) 0.057
α-Fetoprotein level
  ≥ 400 ng/mL Reference  
  < 400 ng/mL 1.168 (0.643, 2.121) 0.610
Treatment method
 TACE-alone Reference  
 TACE-camrelizumab 1.206(0.599,2.428) 0.600
  1. Note. HR: Hazard ratio; CI: Confidence interval; ECOG: Eastern Cooperative Oncology Group; TB: Total bilirubin; PT: Prothrombin time; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; BCLC: Barcelona Clinic Liver Cancer; PLR: Platelet-to-lymphocyte ratio; NLR: Neutrophil-to-lymphocyte ratio